Suppr超能文献

F-FDOPA PET 和 MRI 特征与肿瘤恶性程度相关,并可预测未经治疗的脑胶质瘤患者的生存情况:一项横断面研究。

F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.

机构信息

Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

出版信息

J Neurooncol. 2018 Sep;139(2):399-409. doi: 10.1007/s11060-018-2877-6. Epub 2018 Apr 20.

Abstract

INTRODUCTION

To report the potential value of pre-operative F-FDOPA PET and anatomic MRI in diagnosis and prognosis of glioma patients.

METHODS

Forty-five patients with a pathological diagnosis of glioma with pre-operative F-FDOPA PET and anatomic MRI were retrospectively examined. The volume of contrast enhancement and T2 hyperintensity on MRI images along with the ratio of maximum F-FDOPA SUV in tumor to normal tissue (T/N SUV) were measured and used to predict tumor grade, molecular status, and overall survival (OS).

RESULTS

A significant correlation was observed between WHO grade and: the volume of contrast enhancement (r = 0.67), volume of T2 hyperintensity (r = 0.42), and F-FDOPA uptake (r = 0.60) (P < 0.01 for each correlation). The volume of contrast enhancement and F-FDOPA T/N SUV were significantly higher in glioblastoma (WHO IV) compared with lower grade gliomas (WHO I-III), as well as for high-grade gliomas (WHO III-IV) compared with low-grade gliomas (WHO I-II). Receiver-operator characteristic (ROC) analyses confirmed the volume of contrast enhancement and F-FDOPA T/N SUV could each differentiate patient groups. No significant differences in F-FDOPA uptake were observed by IDH or MGMT status. Multivariable Cox regression suggested age (HR 1.16, P = 0.0001) and continuous measures of F-FDOPA PET T/N SUV (HR 4.43, P = 0.016) were significant prognostic factors for OS in WHO I-IV gliomas.

CONCLUSIONS

Current findings suggest a potential role for the use of pre-operative F-FDOPA PET in suspected glioma. Increased F-FDOPA uptake may not only predict higher glioma grade, but also worse OS.

摘要

介绍

报告术前 F-FDOPA PET 和解剖 MRI 在诊断和预测胶质瘤患者预后中的潜在价值。

方法

回顾性检查了 45 例术前 F-FDOPA PET 和解剖 MRI 检查的病理诊断为胶质瘤的患者。测量 MRI 图像上的对比增强和 T2 高信号体积以及肿瘤与正常组织之间的最大 F-FDOPA SUV 比值(T/N SUV),用于预测肿瘤分级、分子状态和总生存期(OS)。

结果

发现 WHO 分级与:对比增强体积(r=0.67)、T2 高信号体积(r=0.42)和 F-FDOPA 摄取(r=0.60)之间存在显著相关性(每项相关性 P<0.01)。与低级别胶质瘤(WHO I-III)相比,胶质母细胞瘤(WHO IV)的对比增强体积和 F-FDOPA T/N SUV 明显更高,与低级别胶质瘤(WHO I-II)相比,高级别胶质瘤(WHO III-IV)的对比增强体积和 F-FDOPA T/N SUV 也明显更高。受试者工作特征(ROC)分析证实,对比增强体积和 F-FDOPA T/N SUV 均能区分患者群体。IDH 或 MGMT 状态对 F-FDOPA 摄取无显著差异。多变量 Cox 回归表明,年龄(HR 1.16,P=0.0001)和 F-FDOPA PET T/N SUV 的连续测量(HR 4.43,P=0.016)是 WHO I-IV 级胶质瘤 OS 的显著预后因素。

结论

目前的研究结果表明,术前 F-FDOPA PET 在疑似胶质瘤中的应用具有潜在作用。F-FDOPA 摄取增加不仅可以预测更高的胶质瘤分级,而且可能预示着更差的 OS。

相似文献

引用本文的文献

9
Advanced Magnetic Resonance Imaging in Pediatric Glioblastomas.小儿胶质母细胞瘤的高级磁共振成像
Front Neurol. 2021 Nov 10;12:733323. doi: 10.3389/fneur.2021.733323. eCollection 2021.

本文引用的文献

5
FDOPA PET-CT of Nonenhancing Brain Tumors.非强化脑肿瘤的 FDOPA PET-CT。
Clin Nucl Med. 2017 Apr;42(4):250-257. doi: 10.1097/RLU.0000000000001540.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验